Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Spindle Assembly Checkpoint Proteins May Be Targeted by New Anticancer Drugs

By LabMedica International staff writers
Posted on 09 May 2012
Data published in a recent paper on the molecular factors that control chromosome segregation during cell division may help drug developers in their efforts to replace the taxane family of chemotherapeutic agents with similarly effective but less toxic drugs.

The primary taxane is paclitaxel, a naturally occurring compound originally extracted from the bark of the Pacific yew tree (Taxus spp.). More...
Due to high demand, paclitaxel is typically synthesized from the more abundant, naturally occurring compound 10-deacetyl baccatin III, which is extracted from the needles of yew plants. Paclitaxel and the closely related compound docetaxel disrupt microtubule function, which inhibits replication of cancer cells. However, this class of drug can have debilitating side effects including permanent neurological damage and hair loss.

Fine-tuning of drugs to replace the taxanes requires better understanding of the molecular processes that control chromosome segregation during cell division. To this end investigators at the University of Warwick (United Kingdom) have been studying the alphabet soup of proteins – including Mad1, Mad2, Mad3 (BubR1), Bub3, and the kinases Bub1, Mph1 (Mps1), and Aurora B – that comprise the spindle assembly checkpoint (SAC). SAC is the major surveillance system that ensures that sister chromatids do not separate until all chromosomes are correctly oriented during mitosis.

Details of how these proteins interact to maintain SAC activity were published in the April 19, 2012, online edition of the journal Current Biology.

Senior author Dr. Jonathan Millar, professor of cell biology at the University of Warwick said, “Components of the spindle assembly checkpoint were first discovered 22 years ago by researchers in America and yet, until now, the binding sites for these proteins on chromosomes have remained unknown. We have been able to answer this question and as a result, we are now in a much better position to design more selective and effective drugs. This research is a significant advance in our understanding of how the spindle checkpoint operates but it is really just the start. More research has to be done before we can convert this into a commercial treatment for patients. But we are greatly encouraged that our research here at Warwick is leading the way in the search for more effective cancer drugs.”

Related Links:

University of Warwick



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.